Cormark Upgrades BioRem (CVE:BRM) to Moderate Buy

BioRem (CVE:BRM) was upgraded by research analysts at Cormark to a “moderate buy” rating in a research report issued to clients and investors on Tuesday,Zacks.com reports.

BioRem Price Performance

Shares of CVE BRM traded down C$0.05 during mid-day trading on Tuesday, reaching C$3.07. The company’s stock had a trading volume of 22,645 shares, compared to its average volume of 32,655. BioRem has a 1-year low of C$0.95 and a 1-year high of C$3.39. The stock has a market capitalization of C$48.20 million, a P/E ratio of 14.62 and a beta of 0.85. The company has a debt-to-equity ratio of 48.97, a quick ratio of 1.08 and a current ratio of 1.57. The stock has a 50-day moving average of C$2.82 and a two-hundred day moving average of C$2.40.

Insider Activity

In other BioRem news, Director Derek Webb sold 120,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of C$2.93, for a total value of C$351,600.00. Insiders own 1.90% of the company’s stock.

About BioRem

BioRem Inc, a clean technology engineering company, designs, manufactures, distributes, and sells air pollution control systems that are used to eliminate odors, volatile organic compounds (VOCs), and hazardous air pollutants (HAPs). It offers biofilters for the removal of odors, H2S, VOCs, and HAPs; and biotrickling filters for applications of high levels of H2S or other water-soluble VOCs.